Invesco
ADAP

Invesco’s Adaptimmune Therapeutics ADAP Stock Holding History

Invesco’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-78,031
Closed -$15.4K – 3761
2025
Q1 		$15.4K Buy
78,031
+14,696
+23% +$7.61K ﹤0.01% 3751
2024
Q4 		$34.1K Buy
63,335
+28,526
+82% +$20.8K ﹤0.01% 3721
2024
Q3 		$33.1K Buy
34,809
+66
+0.2% +$75 ﹤0.01% 3723
2024
Q2 		$33.9K Buy
+34,743
New +$38.1K ﹤0.01% 3855
2023
Q4 		– Sell
-45,906
Closed -$35.8K – 3823
2023
Q3 		$35.8K Buy
45,906
+10,914
+31% +$9.16K ﹤0.01% 3819
2023
Q2 		$32.4K Buy
+34,992
New +$41.7K ﹤0.01% 3842
2020
Q2 		– Sell
-17,448
Closed -$47K – 3637
2020
Q1 		$47K Buy
+17,448
New +$57.9K ﹤0.01% 3610

Other funds holding ADAP

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Invesco's ADAP Position: Q2 2025 in Review

Invesco sold out of Adaptimmune Therapeutics (ADAP) in Q2 2025, closing a stake of 78,031 shares — an estimated $15.4K sold.

Invesco first reported a position in ADAP in Q1 2020 and held it in 7 quarters. The position peaked at $47K in Q1 2020. 65 funds tracked by Wall St. Rank hold ADAP as of Q2 2025.

  • Invesco reported no remaining Adaptimmune Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Invesco sold 78,031 Adaptimmune Therapeutics shares in Q2 2025, an estimated $15.4K.
  • Invesco first reported a position in Adaptimmune Therapeutics in Q1 2020 and held it in 7 quarters.
  • Invesco's Adaptimmune Therapeutics position peaked at $47K in Q1 2020.
  • 65 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q2 2025.

Based on Invesco's 13F filing for Q2 2025, filed 13 Aug 2025.